Literature DB >> 33571472

Endophthalmitis Prophylaxis Failures in Patients Injected With Intracameral Antibiotic During Cataract Surgery.

Neal H Shorstein1, Liyan Liu2, James A Carolan2, Lisa Herrinton2.   

Abstract

PURPOSE: To estimate the association of cefuroxime and moxifloxacin in relation to the occurrence of endophthalmitis following phacoemulsification cataract surgery.
DESIGN: Retrospective clinical cohort study.
METHODS: We studied patients with noncomplex phacoemulsification cataract surgery in Kaiser Permanente Northern California during 2014-2019. Data were obtained for acute, postoperative endophthalmitis within 90 days of phacoemulsification, including culture and antibiogram results, intracameral and topical antibiotic agent, and dose. In a post hoc analysis, we also examined preoperative anterior chamber depth (ACD) and postoperative anterior chamber volume (ACV).
RESULTS: Of 216,141 surgeries, endophthalmitis occurred in 0.020% of moxifloxacin-injected eyes and 0.013% of cefuroxime eyes (relative risk 1.62 with 95% CI 0.82-3.20, P = .16). Of the 34 (0.016%) cases of endophthalmitis, cefuroxime 1 mg was injected into 13 eyes and moxifloxacin 0.1% into 21 eyes. Organisms with antibiograms were identified in 12 (35%) cases. Of these, bacteria recovered from cefuroxime-injected eyes were resistant to cefuroxime in all cases (4/4), with Enterococcus comprising half of these. In eyes injected with moxifloxacin 0.1%, 6 out of 7 organisms were sensitive to moxifloxacin injected with 0.1 mL and in 1 eye injected with 1 mL. Streptococcus was the most common organism recovered (6/9) in moxifloxacin-injected eyes. Preoperative ACD and postoperative calculated ACV were higher in eyes injected with moxifloxacin.
CONCLUSIONS: Endophthalmitis cases with positive cultures were generally related to organism resistance in cefuroxime eyes but to sensitive organisms in moxifloxacin eyes. Moxifloxacin doses may have been insufficient in eyes with larger ACV.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33571472      PMCID: PMC8184599          DOI: 10.1016/j.ajo.2021.02.007

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.488


  33 in total

1.  Evaluation of the safety of prophylactic intracameral moxifloxacin in cataract surgery.

Authors:  Stephen S Lane; Robert H Osher; Samuel Masket; Shaleen Belani
Journal:  J Cataract Refract Surg       Date:  2008-09       Impact factor: 3.351

2.  Safety of intracameral moxifloxacin for prophylaxis of endophthalmitis after cataract surgery.

Authors:  Lisa Brothers Arbisser
Journal:  J Cataract Refract Surg       Date:  2008-07       Impact factor: 3.351

3.  Comparative corneal endothelial cell toxicity of differing intracameral moxifloxacin doses after phacoemulsification.

Authors:  David F Chang; N Venkatesh Prajna; Loretta B Szczotka-Flynn; Beth Ann Benetz; Jonathan H Lass; Robert C OʼBrien; Harry J Menegay; Susanne Gardner; Madhu Shekar; Sharmila Rajendrababu; Douglas J Rhee
Journal:  J Cataract Refract Surg       Date:  2020-03       Impact factor: 3.351

4.  Safety and efficacy of intracameral moxifloxacin for prevention of post-cataract endophthalmitis: Randomized controlled clinical trial.

Authors:  Mathias V Melega; Monica Alves; Rodrigo Pessoa Cavalcanti Lira; Iuri Cardoso da Silva; Bruna Gil Ferreira; Hermano Lg Assis Filho; Fernando Rodrigo Pedreira Chaves; Alexandre A F Martini; Livia Maria Dias Freire; Roberto Dos Reis; Carlos Eduardo Leite Arieta
Journal:  J Cataract Refract Surg       Date:  2019-01-25       Impact factor: 3.351

5.  Toxicity of Intracameral Injection of Fourth-Generation Fluoroquinolones on the Corneal Endothelium.

Authors:  Francisco Bandeira E Silva; Linda Christian Carrijo-Carvalho; Anderson Teixeira; Denise de Freitas; Fabio Ramos de Souza Carvalho
Journal:  Cornea       Date:  2016-12       Impact factor: 2.651

6.  Comparative Effectiveness of Antibiotic Prophylaxis in Cataract Surgery.

Authors:  Lisa J Herrinton; Neal H Shorstein; John F Paschal; Liyan Liu; Richard Contreras; Kevin L Winthrop; William J Chang; Ronald B Melles; Donald S Fong
Journal:  Ophthalmology       Date:  2015-10-14       Impact factor: 12.079

7.  Budget impact assessment of Aprokam® compared with unlicensed cefuroxime for prophylaxis of post-cataract surgery endophthalmitis.

Authors:  Christine Purslow; Keith Davey; Mildred Johnson; Guilhem Pietri; Gaurav Suri
Journal:  BMC Ophthalmol       Date:  2015-07-08       Impact factor: 2.209

8.  Clear-cornea cataract surgery: pupil size and shape changes, along with anterior chamber volume and depth changes. A Scheimpflug imaging study.

Authors:  Anastasios John Kanellopoulos; George Asimellis
Journal:  Clin Ophthalmol       Date:  2014-10-24

Review 9.  Antibiotic prophylaxis in cataract surgery - An evidence-based approach.

Authors:  Aravind Haripriya
Journal:  Indian J Ophthalmol       Date:  2017-12       Impact factor: 1.848

10.  Acute Endophthalmitis after Cataract Surgery: Clinical Characteristics and the Role of Intracameral Antibiotic Prophylaxis.

Authors:  Stefan J R de Geus; Joost Hopman; Roger J Brüggemann; B Jeroen Klevering; Niels Crama
Journal:  Ophthalmol Retina       Date:  2020-09-19
View more
  2 in total

1.  Incidence of endophthalmitis after phacoemulsification cataract surgery: a Meta-analysis.

Authors:  Si-Lu Shi; Xiao-Ning Yu; Yi-Lei Cui; Si-Fan Zheng; Xing-Chao Shentu
Journal:  Int J Ophthalmol       Date:  2022-02-18       Impact factor: 1.779

2.  Prophylactic antibiotics for postcataract surgery endophthalmitis: a systematic review and network meta-analysis of 6.8 million eyes.

Authors:  Ai Kato; Nobuyuki Horita; Ho Namkoong; Eiichi Nomura; Nami Masuhara; Takeshi Kaneko; Nobuhisa Mizuki; Masaki Takeuchi
Journal:  Sci Rep       Date:  2022-10-18       Impact factor: 4.996

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.